Indication
Pavblu is indicated for adults for the treatment of neovascular (wet) age-related macular degeneration (AMD) (see section 5.1), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (see section 5.1), visual impairment due to diabetic macular oedema (DME) (see section 5.1), visual impairment due to myopic choroidal neovascularisation (myopic CNV) (see section 5.1).
In other countries
The same active substances on other registers, the same brand first.
National listings
The national registers that list this EU medicine.
- Pavblu 40 MG/ML Solucion Inyectable en Jeringa PrecargadaSpain · 7 mgAuthorised
- Pavblu 40 MG/ML Solucion Inyectable en VialSpain · 11,10 mgAuthorised
- PAVBLU 40 mg/ml oplossing voor injectie in een injectieflaconNetherlandsAuthorised
- PAVBLU 40 mg/ml oplossing voor injectie in voorgevulde spuitNetherlandsAuthorised